Corvus Pharmaceuticals, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Corvus Pharmaceuticals, Inc. (CRVS) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 777.84 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-03-31 was 3.03M shares.
- Corvus Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2025 was 777.84K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | 777.84K shares 10-K · filed 2026-03-12 | |||
| 2025-09-30 | 1.04M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 1.56M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 3.03M shares 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |